Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 13/2011

01.09.2011 | Adis Drug Evaluation

Ustekinumab

A Review of its Use in the Management of Moderate To Severe Plaque Psoriasis

verfasst von: Jamie D. Croxtall

Erschienen in: Drugs | Ausgabe 13/2011

Einloggen, um Zugang zu erhalten

Abstract

Ustekinumab (Stelara™) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23. It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the EU, it is indicated for those who failed to respond to, have a contraindication to or are intolerant of other systemic therapies or phototherapy. This article reviews the efficacy and tolerability of ustekinumab in patients with moderate to severe plaque psoriasis, as well as summarizing its pharmacological properties.
Ustekinumab attenuates the immune cell activation properties of IL-12 and IL-23. It interrupts the abnormal activation of signalling and cytokine cascades that underlie the pathology of psoriasis by reducing the expression of IL-12-and IL-23-induced cell surface markers that mediate skin homing, activation and cytokine release.
In well designed, randomized clinical trials, regimens of subcutaneous ustekinumab 45 or 90 mg provided a rapid and durable improvement in psoriasis area severity index (PASI) scores for patients with moderate to severe plaque psoriasis. A significantly greater proportion of patients receiving ustekinuman 45 or 90 mg compared with those receiving placebo achieved a ≥75% improvement from baseline in PASI score following 12 weeks’ treatment (primary endpoint). Improvements in PASI scores were evident following 2 weeks’ treatment with ustekinumab and were sustained for up to 3 years. Treatment with ustekinumab 45 or 90 mg also improved health-related quality-of-life scores from baseline. Following 12 weeks’ treatment, ustekinumab 45 or 90 mg was more effective than etanercept 50 mg twice weekly in providing symptomatic relief for patients with moderate to severe plaque psoriasis. Furthermore, ustekinumab treatment provided effective symptomatic improvement for almost half of the patients who showed no response to 12 weeks’ treatment with etanercept. More limited data indicate that ustekinumab also improves the symptoms of arthritis in patients with plaque psoriasis and psoriatic arthritis.
Subcutaneous ustekinumab was generally well tolerated in clinical trials; most adverse events were mild in intensity and did not require dosage adjustment. A pooled analysis of clinical trial data indicated no specific patterns of infection for recipients of ustekinumab and that infection rates remained stable following cumulative exposure to the agent.
In conclusion, subcutaneous ustekinumab provides an effective and well tolerated alternative for the symptomatic treatment of patients with moderate to severe plaque psoriasis.
Literatur
1.
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May; 58(5): 826–50
2.
Jagou M, Bastuji-Garin S, Bourdon-Lanoy E, et al. Poor agreement between self-reported and dermatologists’ diagnoses for five common dermatoses. Br J Dermatol 2006 Nov; 155(5): 1006–12PubMedCrossRef
3.
4.
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 2009 Feb; 60(2): 218–24PubMedCrossRef
5.
6.
Langley RG, Dauden E. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy. Dermatology 2010; 221 Suppl. 1: 29–42PubMedCrossRef
7.
Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005 Oct; 53(4): 573PubMedCrossRef
8.
Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009 Jul; 129(7): 1601–3PubMedCrossRef
9.
Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008 Dec; 144(12): 1571–5PubMedCrossRef
10.
Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 Mar; 137(3): 280–4PubMed
11.
Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998 Nov; 139(5): 846–50PubMedCrossRef
12.
Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004 Aug; 45(3): 155–9; quiz 160-1PubMedCrossRef
13.
Magin PJ, Pond CD, Smith WT, et al. A cross-sectional study of psychological morbidity in patients with acne, psoriasis and atopic dermatitis in specialist dermatology and general practices. J Eur Acad Dermatol Venereol 2008 Dec; 22(12): 1435–44PubMedCrossRef
14.
Kurzeja M, Rudnicka L, Olszewska M. New interleukin 23-pathway inhibitors in dermatology: ustekinumab, briakinumab and secukinumab. Am J Clin Derm 2011 Jan; 12(2): 113–25CrossRef
15.
Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther 2009; 22(5): 431–40PubMedCrossRef
16.
Garcia-Valladares I, Cuchacovich R, Espinoza LR. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther 2011; 5: 41–9PubMed
17.
18.
Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008 Feb; 144(2): 200–7PubMedCrossRef
19.
Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007 Dec; 57(6): 1059–68PubMedCrossRef
20.
Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007 Feb; 80(2): 273–90PubMedCrossRef
21.
Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003 Feb; 3(2): 133–46PubMedCrossRef
22.
Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003 Jan 17; 278(3): 1910–4PubMedCrossRef
23.
Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000 Nov; 13(5): 715–25PubMedCrossRef
24.
Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci 2011 Mar; 1222(1): 30–9PubMedCrossRef
25.
Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007 Feb 15; 178(4): 2229–40PubMed
26.
Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006 Oct 1; 177(7): 4917–26PubMed
27.
Lyakh L, Trinchieri G, Provezza L, et al. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008 Dec; 226: 112–31PubMedCrossRef
28.
Presky DH, Yang H, Minetti LJ, et al. A functional inter-leukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 1996 Nov 26; 93(24): 14002–7PubMedCrossRef
29.
Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002 Jun 1; 168(11): 5699–708PubMed
30.
31.
32.
Luo J, Wu SJ, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010 Oct 8; 402(5): 797–812PubMedCrossRef
33.
Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12-and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007 May; 247(1): 1–11PubMedCrossRef
34.
Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007 May; 23(5): 1081–92PubMedCrossRef
35.
36.
Yates CC, Whaley D, Kulasekeran P, et al. Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor. Am J Pathol 2007 Aug; 171(2): 484–95PubMedCrossRef
37.
Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010 May; 37(5): 413–25PubMedCrossRef
38.
Brodmerkel C, Zhu Y, Jiao Q, et al. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. J Drugs Dermatol 2010 Jun; 9(6): 677–83PubMed
39.
40.
Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009 Feb; 49(2): 162–75PubMedCrossRef
41.
Zhou H, Hu C, Zhu Y, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2010 Mar; 50(3): 257–67PubMedCrossRef
42.
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 May 17; 371(9625): 1665–74PubMedCrossRef
43.
Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 May 17; 371(9625): 1675–84PubMedCrossRef
44.
Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010 Jan 14; 362(2): 118–28PubMedCrossRef
45.
Ghislain P, Poulin Y, Wasel N, et al. Maintenance of long-term efficacy of ustekinumab through year 3 for patients with moderate-to-severe psoriasis [abstract no. P589]. 19th Congress of the European Academy of Dermatology and Venerology; 2010 Oct 6–10; Gothenburg
46.
Rich P, Guzzo C, Wang Y, et al. Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a phase 3 trial. American Academy of Dermatology Summer Academy Meeting; 2008 Jul 30–Aug 3; Chicago (IL)
47.
Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010 Jan; 162(1): 137–46PubMedCrossRef
48.
Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010 Sep; 63(3): 457–65PubMedCrossRef
49.
Guenther L, Han C, Szapary P, et al. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol 2011 Apr 27; 25(7): 851–7PubMedCrossRef
50.
Reich K, Schenkel B, Zhao N, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. Epub 2010 Oct 31
51.
Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010 Oct; 63(4): 571–9PubMedCrossRef
52.
Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 Feb; 373(9664): 633–40PubMedCrossRef
53.
Gottlieb A, Mendelsohn A, Shen Y-K, et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, significantly improves overall skin response and health related quality of life in patients with psoriatic arthritis [abstract no. FP1333]. 17th Congress of the European Academy of Dermatology and Venereology; 2008 Sep 17–21; Paris
54.
Gottlieb A, Menter A, Mendelsohn A, et al. Efficacy of ustekinumab, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis patients with baseline C-reactive protein >=0.4 vs <0.4 mg/dL: results of a post hoc analysis of data from a phase 2, randomized, double-blind, placebo-controlled study [abstract no. SAT0340]. Annual European Congress of the European League Against Rheumatism; 2009 Jun 10–13; Copenhagen
55.
Rich P, Feldman S, Vender R, et al. Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis [abstract no. P 040]. J Eur Acad Dermatol Venerol 2010 Jul; 24 Suppl. 4: 1–83
56.
Krueger G, Langley R, Leonardi C, et al. A human inter-leukin-12/23 monolclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356(6): 580–92PubMedCrossRef
57.
Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011 Feb 17; 164(4): 862–72PubMedCrossRef
58.
Gordon K, Menter A, Szapary PO, et al. Infection rates in ustekinumab-treated psoriasis patients: observations with up to 3 years of follow-up and comparisons to a large health care claims database [abstract no. P 051]. J Eur Acad Dermatol Venerol 2010 Jul; 24 Suppl. 4: 1–83
59.
Reich K, Leonardi C, Griffiths C, et al. Update on the cumulative safety experience of ustekinumab: results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up [abstract no. FC07-03]. 22nd World Congress of Dermatology; 2011 May 24–29; Seoul
60.
Papp K, Ho V, Yeilding N, et al. Malignancies in ustekinumab-treated moderate-to-severe psoriasis patients: observations with up to 3 years of follow-up and comparisons to the general United States population [abstract no. P554]. 19th Congress of the European Academy of Dermatology and Venereology; 2010 Oct 6–10; Gothenburg
61.
Gordon K, Baker D, Guenther L, et al. Sustained efficacy of ustekinumab for the treatment of moderate to severe psoriasis in initial responders continuing with maintenance therapy through year 3 [abstract no. P3345]. J Am Acad Dermatol 2011 Feb; 64 (2 Suppl. 1): AB156
62.
Bissonnette R, Lambert J, Yeilding N, et al. Effect of ustekinumab on commonly measured laboratory parameters: three year results from the PHOENIX 1 trial [abstract no. P 048]. Congress of the Psoriasis International Network; 2010 Jul 1–4; Paris
63.
Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003 Nov; 49(5): 897–9PubMedCrossRef
64.
Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006 Jun; 298(1): 7–15PubMedCrossRef
65.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011 Jul; 65(1): 137–74
66.
Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 2005 Mar; 52 (3 Pt 1): 434–44PubMedCrossRef
67.
Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005 Apr; 152(4): 597–615PubMedCrossRef
68.
Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007 Jul 21; 370(9583): 272–84PubMedCrossRef
69.
Tsourounis C, Cheng C. Biologic therapies for the treatment of chronic plaque psoriasis. Formulary 2005; 40(6): 184–99
70.
Croom KF, McCormack PL. Adalimumab: in plaque psoriasis. Am J Clin Dermatol 2009; 10(1): 43–50PubMedCrossRef
71.
Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics 2008 Mar; 2(1): 115–24PubMed
72.
Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005; 6(2): 121–36PubMedCrossRef
73.
74.
Centocor Ortho Biotech Services. Psoriasis Longitudinal Assessment and Registry (PSOLAR) [ClinicalTrials.gov indentifier NCT00508547]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2011 Jul 29]
75.
Shear NH. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2006; 29(1): 49–66PubMedCrossRef
76.
Fraser K. 68th Annual Meeting of the American Academy of Dermatology: Miami Beach, Florida, USA, 5–9 March 2010. Am J Clin Dermatol 2010; 11(3): 223–4PubMedCrossRef
77.
78.
Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009 Nov; 161(5): 987–1019PubMedCrossRef
79.
Martin S, Feldman SR, Augustin M, et al. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat 2011; 22(3): 138–43PubMedCrossRef
Metadaten
Titel
Ustekinumab
A Review of its Use in the Management of Moderate To Severe Plaque Psoriasis
verfasst von
Jamie D. Croxtall
Publikationsdatum
01.09.2011
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 13/2011
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11207530-000000000-00000

Weitere Artikel der Ausgabe 13/2011

Drugs 13/2011 Zur Ausgabe

Review Article

Pharmacological Modulation of Arterial Stiffness

Adis Drug Evaluation

Eldecalcitol

Adis Drug Evaluation

Dasatinib

Adis Drug Profile

Pirfenidone

Review Article

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus

Erratum

Erratum to: Cabazitaxel: a novel microtubule inhibitor